The emerging roles of DOT1L in leukemia and normal development

Leukemia

Volumn 28, Issue 11, 2014, Pages 2131-2138

  McLean, C M ^a   Karemaker, I D ^a   van Leeuwen, F ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOT1L PROTEIN, HUMAN; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN;

DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; HUMAN; LEUKEMIA; METABOLISM; PHYSIOLOGY;

DNA METHYLATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HUMANS; LEUKEMIA; METHYLTRANSFERASES; MYELOID-LYMPHOID LEUKEMIA PROTEIN;

EID: 84922291676     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.169     Document Type: Review

References (64)

1. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396–398. DOI: 10.1038/nature05913
2. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009; 23: 781–783. DOI: 10.1101/gad.1787609
3. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343–357. DOI: 10.1038/nrg3173
4. Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002; 12: 1052–1058. DOI: 10.1016/S0960-9822(02)00901-6
5. Singer MS, Kahana A, Wolf AJ, Meisinger LL, Peterson SE, Goggin C et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 1998; 150: 613–632.
6. Lacoste N, Utley RT, Hunter JM, Poirier GG, Côte J. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J Biol Chem 2002; 277: 30421–30424. DOI: 10.1074/jbc.C200366200
7. Van Leeuwen F, Gafken PPR, Gottschling DE DE. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 2002; 109: 745–756. DOI: 10.1016/S0092-8674(02)00759-6
8. Nguyen A, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 3: 1345–1358. DOI: 10.1101/gad.2057811
9. Kim W, Choi M, Kim J-E. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle. Cell Cycle 2014; 13: 726–738. DOI: 10.4161/cc.28104
10. Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 2008; 28: 2825–2839. DOI: 10.1128/MCB.02076-07
11. Tatum D, Li S. Evidence that the histone methyltransferase Dot1 mediates global genomic repair by methylating histone H3 on lysine 79. J Biol Chem 2011; 286: 17530–17535. DOI: 10.1074/jbc.M111.241570
12. Schulze JM, Jackson J, Nakanishi S, Gardner JM, Hentrich T, Haug J et al. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Mol Cell 2009; 35: 626–641. DOI: 10.1016/j.molcel.2009.07.017
13. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167–178. DOI: 10.1016/j.cell.2005.02.020
14. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 2006; 8: 1017–1024. DOI: 10.1038/ncb1464
15. Daigle SR, Olhava EJ, Therkelsen Ca, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53–65. DOI: 10.1016/j.ccr.2011.06.009
16. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 2013; 27: 813–822. DOI: 10.1038/leu.2012.327
17. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA et al. Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood 2013; 122: 1017–1025. DOI: 10.1182/blood-2013-04-497644
18. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154–156. DOI: 10.1038/292154a0
19. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981; 78: 7634–7638. DOI: 10.1073/pnas.78.12.7634
20. Jones B, Su H, Bhat A, Lei H, Bajko J, Hevi S et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 2008; 4: e1000190. DOI: 10.1371/journal.pgen.1000190
21. Barry ER, Krueger W, Jakuba CM, Veilleux E, Ambrosi DJ, Nelson CE et al. ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L. Stem Cells 2009; 27: 1538–1547. DOI: 10.1002/stem.86
22. Savatier P, Lapillonne H, Van Grunsven LA, Rudkin BB, Samarut J. Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells. Oncogene 1996; 12: 309–322.
23. Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 2012; 22: 37–50. DOI: 10.1089/scd.2012.0375
24. Kim W, Kim R, Park G, Park J-W, Kim J-E. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J Biol Chem 2012; 287: 5588–5599. DOI: 10.1074/jbc.M111.328138
25. Chang M-J, Wu H, Achille NJ, Reisenauer MR, Chou C-W, Zeleznik-Le NJ et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res 2010; 70: 10234–10242. DOI: 10.1158/0008-5472.CAN-10-3294
26. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66–78. DOI: 10.1016/j.ccr.2011.06.010
27. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011; 117: 4759–4768. DOI: 10.1182/blood-2010-12-327668
28. Nguyen AT, Xiao B, Neppl RL, Kallin EM, Li J, Chen T et al. DOT1L regulates dystrophin expression and is critical for cardiac function. Genes Dev 2011; 25: 263–274. DOI: 10.1101/gad.2018511
29. Ho L-L, Sinha A, Verzi M, Bernt KM, Armstrong S, Shivdasani Ra. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol 2013; 33: 1735–1745. DOI: 10.1128/MCB.01463-12
30. Kim J, Orkin SH. Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome Med 2011; 3: 75. DOI: 10.1186/gm291
31. Onder TTT, Kara N, Cherry A, Sinha AUA, Zhu N, Bernt KM et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012; 483: 598–602. DOI: 10.1038/nature10953
32. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861–872. DOI: 10.1016/j.cell.2007.11.019
33. Ooga M, Inoue A, Kageyama S, Akiyama T, Nagata M, Aoki F. Changes in H3K79 methylation during preimplantation development in mice. Biol Reprod 2008; 78: 413–424. DOI: 10.1095/biolreprod.107.063453
34. Ontoso D, Kauppi L, Keeney S, San-Segundo PA. Dynamics of DOT1L localization and H3K79 methylation during meiotic prophase I in mouse spermatocytes. Chromosoma 2013; 123: 147–164. DOI: 10.1007/s00412-013-0438-5
35. Shanower Ga, Muller M, Blanton JL, Honti V, Gyurkovics H, Schedl P. Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase. Genetics 2005; 169: 173–184. DOI: 10.1534/genetics.104.033191
36. Zhang W, Hayashizaki Y, Kone BBC. Structure and regulation of the mDot1 gene, a mouse histone H3 methyltransferase. Biochem J 2004; 377: 1–36. DOI: 10.1042/bj20031000
37. Feng Y, Yang Y. Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood 2010; 116: 4483–4491. DOI: 10.1182/blood-2010-03-276501
38. Hove JR, Köster RW, Forouhar AS, Acevedo-Bolton G, Fraser SE, Gharib M. Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis. Nature 2003; 421: 172–177. DOI: 10.1038/nature01282
39. Illi B, Scopece A, Nanni S, Farsetti A, Morgante L, Biglioli P et al. Epigenetic histone modification and cardiovascular lineage programming in mouse embryonic stem cells exposed to laminar shear stress. Circ Res 2005; 96: 501–508. DOI: 10.1161/01.RES.0000159181.06379.63
40. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 2013; 498: 220–223. DOI: 10.1038/nature12141
41. Zhu B, Zheng Y, Pham A-D, Mandal SS, Erdjument-Bromage H, Tempst P et al. Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell 2005; 20: 601–611. DOI: 10.1016/j.molcel.2005.09.025
42. Castaño MC, Cailotto F, Kerkhof HJ, Cornelis FMF. Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci 2012; 109: 8218–8223. DOI: 10.1073/pnas.1119899109
43. Lin Y-W, Aplan PD. Leukemic transformation. Cancer Biol Ther 2004; 3: 13–20. DOI: 10.4161/cbt.3.1.537
44. Barry ER, Corry GN, Rasmussen TP. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opin Ther Targets 2010; 14: 405–418. DOI: 10.1517/14728221003623241
45. Walsh J, DeKoter R, Lee H, Smith E. Cooperative and antagonistic interplay between PU. 1 and GATA-2 in the specification of myeloid cell fates. Immunity 2002; 17: 665–676. DOI: 10.1016/S1074-7613(02)00452-1
46. Nguyen AT, He J, Taranova O, Zhang Y. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res 2011; 21: 1370–1373. DOI: 10.1038/cr.2011.115
47. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989; 8: 2283–2290. DOI: 10.1002/j.1460-2075.1989.tb08354.x
48. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012; 3: 1288. DOI: 10.1038/ncomms2304
49. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and ‘oncogenic shock’. Biochem Pharmacol 2010; 80: 666–673. DOI: 10.1016/j.bcp.2010.03.001
50. Stulemeijer IJE, Pike BL, Faber AW, Verzijlbergen KF, Welsem T, Van, Frederiks F et al. Dot1 binding induces chromatin rearrangements by histone methylation- dependent and -independent mechanisms. Epigenetics Chromatin 2011; 4: 2. DOI: 10.1186/1756-8935-4-2
51. Ooga M, Suzuki MG, Aoki F. Involvement of DOT1L in the remodeling of heterochromatin configuration during early preimplantation development in mice. Biol Reprod 2013; 89: 1–10. DOI: 10.1095/biolreprod.113.113258
52. Kim S-K, Jung I, Lee H, Kang K, Kim M, Jeong K et al. Human histone H3K79 methyltransferase DOT1L protein binds actively transcribing RNA polymerase II to regulate gene expression. J Biol Chem 2012; 287: 39698–39709. DOI: 10.1074/jbc.M112.384057
53. Schübeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 2004; 18: 1263–1271. DOI: 10.1101/gad.1198204
54. Zhang W, Xia X, Jalal D. Aldosterone-sensitive repression of ENaCα transcription by a histone H3 lysine-79 methyltransferase. Am J Physiol Cell Physiol 2006; 77030: 936–946. DOI: 10.1152/ajpcell.00431.2005
55. Cecere G, Hoersch S, Jensen MB, Dixit S, Grishok A. The ZFP-1(AF10)/DOT-1 complex opposes H2B ubiquitination to reduce Pol II transcription. Mol Cell 2013; 50: 894–907. DOI: 10.1016/j.molcel.2013.06.002
56. Lu X, Simon MD, Chodaparambil JV, Hansen JC, Shokat KM, Luger K. The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat Struct Mol Biol 2008; 15: 1122–1124. DOI: 10.1038/nsmb.1489
57. Sabra M, Texier P, El Maalouf J, Lomonte P. The tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated histone H3 lysine 79. J Cell Sci 2013; 126: 3664–3677. DOI: 10.1242/jcs.126003
58. Monani UR. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 2005; 48: 885–896. DOI: 10.1016/j.neuron.2005.12.001
59. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598–602. DOI: 10.1038/nature12451
60. Mohan M, Herz H-M, Takahashi Y-H, Lin C, Lai KC, Zhang Y et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 2010; 24: 574–589. DOI: 10.1101/gad.1898410
61. Mahmoudi T, Boj SF, Hatzis P, Li VSW, Taouatas N, Vries RGJ et al. The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential for intestinal homeostasis. PLoS Biol 2010; 8: e1000539. DOI: 10.1371/journal.pbio.1000539
62. Matsuura K, Fujimoto K, Das B, Fu L, Lu CD, Shi Y. Histone H3K79 methyltransferase Dot1L is directly activated by thyroid hormone receptor during Xenopus metamorphosis. Cell Biosci 2012; 2: 25. DOI: 10.1186/2045-3701-2-25
63. Tata JR. Amphibian metamorphosis: An exquisite model for hormonal regulation of postembryonic development in vertebrates. Dev Growth Differ 1996; 38: 223–231. DOI: 10.1046/j.1440-169X.1996.t01-2-00001.x
64. List O, Togawa T, Tsuda M, Matsuo T, Elard L, Aigaki T. Overexpression of grappa encoding a histone methyltransferase enhances stress resistance in Drosophila. Hereditas 2009; 146: 19–28. DOI: 10.1111/j.1601-5223.2008.02080.x